GILD Scores FDA/CHMP Wins, But Core Thesis Unchanged

What happened

Gilead received FDA approval for Hepcludex, the first U.S. therapy for chronic hepatitis delta virus (HDV), and a favorable CHMP opinion for Trodelvy in triple-negative breast cancer (TNBC) in Europe. While these regulatory wins are positive, Hepcludex targets a very small patient population and Trodelvy's European advance stands in contrast to its recent Phase 3 miss in non-small cell lung cancer. The DeepValue master report continues to assess Gilead as a 'WAIT' given that the dominant near-term catalyst remains the Yeztugo HIV PrEP ramp, where payer access and re-dosing persistence data are still unproven. The new approvals modestly diversify the pipeline but do not de-risk the core investment thesis, which hinges on Yeztugo reaching its ~$800M 2026 revenue target. Until mid-2026 evidence on covered lives and second-dose rates emerges, the risk/reward remains balanced.

Implication

The HDV approval and Trodelvy CHMP backing provide pipeline diversification but do not materially shift Gilead's near-term earnings trajectory. The primary value driver remains Yeztugo's adoption curve, which still lacks publicly disclosed persistence and access metrics. Investors should retain a 'WAIT' rating, focusing on 2026 quarterly sales trends and any formulary expansions before adding exposure.

Thesis delta

The thesis remains unchanged: regulatory wins slightly de-risk the non-HIV pipeline but do not alter the central debate around Yeztugo's commercialization. The core issues of payer access and re-dosing persistence still lack evidence, so the 'WAIT' rating and re-assessment window through mid-2026 hold.